Please assess the completion status of the following clinical trial:

Trial Title: Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-80 years~2. NYHA Class II-III HF presenting to the emergency department for worsening HF at baseline~3. On background therapy includes those receiving 40-160 mg of oral furosemide equivalents daily (20-80 mg Torsemide or 1-4 mg Bumetanide).~4. Signs of extracellular volume expansion, defined as one or more of the following:~   1. jugular venous distention~  2. pitting edema (≥1+),~  3. abdominal distension~  4. pulmonary congestion on chest x-ray~  5. pulmonary rales~5. After initial emergency department evaluation and treatment (i.e., at the time of the care transition decision\*), candidates for parenteral diuresis outside of the hospital, defined as all the following:~   1. Oxygen saturation ≥ 90% on exertion~  2. Respiratory Rate \< 24 breaths per minute~  3. Resting Heart Rate \< 100 beats per minute~  4. Systolic Blood Pressure \> 100 mmHg~6. Adequate environment for at-home administration of Furoscix~Exclusion Criteria:~1. Presence of a complicating condition, other than HF that requires immediate hospitalization or anticipated hospitalization in the next 30 days~2. Evidence of acute renal failure as determined at the discretion of the investigator~3. Known allergy to the active and inactive ingredients of the study medication or device adhesive~4. Any local abdominal skin condition on the day of treatment i.e. sunburn, rash, eczema, etc.~5. Currently participating in another interventional research study~6. Women who are pregnant or who could become pregnant and are not willing to use an adequate form of contraception~7. Estimated Creatinine Clearance \< 30 mL per minute by Cockcroft-Gault equation~   CrCl (mL/min) = {(140 - age) x Lean Body Weight (kg)/Serum Creatinine (mg/dL) x 72} (x 0.85 if female)~8. If baseline creatinine value is available: an increase of ≥ 0.5 mg/dL in creatinine from baseline~9. HF requiring immediate hospitalization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Furoscix Infusor Prospective Treatment (Type: EXPERIMENTAL): Furoscix (furosemide injection, 8 mg/mL) administered subcutaneously over 5 hours via the Furoscix Infusor outside the hospital.
- Propensity-Matched Historical Control (Type: NO_INTERVENTION): The control arm will be populated with claims data for patients with HF and fluid overload who presented to the emergency department and were admitted to the hospital for ≤ 72 hours for the treatment of HF with intravenous diuretics. Patients admitted for diuresis-only will be identified by using diagnostic codes for admittance from a claims database.

Based on this trial design, predict the completion outcome and termination type (if applicable).